Monday, 9 April 2012

Thalidomide Celgene 50 mg Hard Capsules





1. Name Of The Medicinal Product



Thalidomide Celgene 50 mg hard capsules


2. Qualitative And Quantitative Composition



Each capsule contains 50 mg of thalidomide.



Excipient:



Each capsule contains 257.2 mg of anhydrous lactose.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Hard capsule.



White opaque capsules marked “Thalidomide 50 mg Celgene”.



4. Clinical Particulars



4.1 Therapeutic Indications



Thalidomide Celgene in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged



Thalidomide Celgene is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).



4.2 Posology And Method Of Administration



Thalidomide treatment must be initiated and monitored under the supervision of physicians with expertise in managing immunomodulatory or chemotherapeutic agents and a full understanding of the risks of thalidomide therapy and monitoring requirements (see section 4.4).



Recommended posology in adults:



The recommended oral dose is 200 mg per day.



A maximum number of 12 cycles of 6 weeks should be used.



Thalidomide Celgene should be taken as a single dose at bedtime, to reduce the impact of somnolence. Thalidomide Celgene can be taken with or without food.



Patients should be monitored for: thromboembolic events; peripheral neuropathy; rash/skin reactions; bradycardia, syncope and somnolence (see sections 4.4 and 4.8). Dose delay, reduction or discontinuation, dependent upon the NCI CTC grade, may be necessary.



Thromboembolic events:



Thromboprophylaxis should be administered for at least the first 5 months of treatment especially in patients with additional thrombotic risk factors. Prophylactic antithrombotic medicinal products, such as low molecular weight heparins or warfarin, should be recommended. The decision to take antithrombotic prophylactic measures should be made after careful assessment of an individual patient's underlying risk factors (see sections 4.4, 4.5 and 4.8).



If the patient experiences any thromboembolic events, treatment must be discontinued and standard anticoagulation therapy started. Once the patient has been stabilised on the anticoagulation treatment and any complications of the thromboembolic event have been managed, the thalidomide treatment may be restarted at the original dose dependent upon a benefit risk assessment. The patient should continue anticoagulation therapy during the course of thalidomide treatment.



Peripheral neuropathy:



Dose modifications due to peripheral neuropathy are described in Table 1.



Table 1: Recommended dose modifications for Thalidomide Celgene related neuropathy in first line treatment of multiple myeloma.














Severity of neuropathy




Modification of dose and regimen




Grade 1 (paraesthesia, weakness and/or loss of reflexes) with no loss of function




Continue to monitor the patient with clinical examination. Consider reducing dose if symptoms worsen. However, dose reduction is not necessarily followed by improvement of symptoms.




Grade 2 (interfering with function but not with activities of daily living)




Reduce dose or interrupt treatment and continue to monitor the patient with clinical and neurological examination. If no improvement or continued worsening of the neuropathy, discontinue treatment. If the neuropathy resolves to Grade 1 or better, the treatment may be restarted, if the benefit/risk is favourable.




Grade 3 (interfering with activities of daily living)




Discontinue treatment




Grade 4 (neuropathy which is disabling)




Discontinue treatment



Elderly:



No specific dose adjustments are recommended for the elderly.



Patients with renal or hepatic impairment:



Thalidomide Celgene has not formally been studied in patients with impaired renal or hepatic function. No specific dose recommendations for these patient populations are available. Patients with severe organ impairment should be carefully monitored for adverse reactions.



Paediatric patients:



Thalidomide Celgene is not recommended for use in children below 18 years of age as safety and efficacy have not been established.



4.3 Contraindications



− Hypersensitivity to thalidomide or to any of the excipients.



− Pregnant women (see section 4.6).



− Women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see sections 4.4 and 4.6).



− Patients unable to follow or comply with the required contraceptive measures (see section 4.4).



4.4 Special Warnings And Precautions For Use





Teratogenic effects:



Thalidomide is a powerful human teratogen, inducing a high frequency of severe and life-threatening birth defects. Thalidomide must never be used by women who are pregnant or by women who could become pregnant unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met. The conditions of the Thalidomide Celgene Pregnancy Prevention Programme must be fulfilled for all male and female patients.



Criteria for women of non-childbearing potential:



A female patient or a female partner of a male patient is considered to have childbearing potential unless she meets at least one of the following criteria:



• Age



• Premature ovarian failure confirmed by a specialist gynaecologist.



• Previous bilateral salpingo-oophorectomy, or hysterectomy.



• XY genotype, Turner's syndrome, uterine agenesis.



*Amenorrhoea following cancer therapy does not rule out childbearing potential.



Counselling:



For women of childbearing potential, thalidomide is contraindicated unless all of the following are met:



• She understands the teratogenic risk to the unborn child



• She understands the need for effective contraception, without interruption, 4 weeks before starting treatment, throughout the entire duration of treatment, and 4 weeks after the end of treatment



• Even if a woman of childbearing potential has amenorrhea she must follow all the advice on effective contraception



• She should be capable of complying with effective contraceptive measures



• She is informed and understands the potential consequences of pregnancy and the need to rapidly consult if there is a risk of pregnancy



• She understands the need to commence the treatment as soon as thalidomide is dispensed following a negative pregnancy test



• She understands the need and accepts to undergo pregnancy testing every 4 weeks



• She acknowledges that she understands the hazards and necessary precautions associated with the use of thalidomide.



As thalidomide is found in semen, male patients taking thalidomide must meet the following conditions:



• Understand the teratogenic risk if engaged in sexual activity with a pregnant woman.



• Understand the need for the use of a condom if engaged in sexual activity with a pregnant woman or a woman of childbearing potential not using effective contraception.



The prescriber must ensure that:



• The patient complies with the conditions of the Thalidomide Celgene Pregnancy Prevention Programme



• The patient confirms that he (she) understand the aforementioned conditions.



Contraception:



Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy and even in case of dose interruption unless the patient commits to absolute and continuous abstinence confirmed on a monthly basis. If not established on effective contraception, the patient must be referred preferably to an appropriately trained healthcare professional for contraceptive advice in order that contraception can be initiated.



The following can be considered to be examples of effective methods of contraception:



• Subcutaneous hormonal implant



• Levonorgestrel-releasing intrauterine system (IUS)



• Medroxyprogesterone acetate depot



• Tubal sterilisation



• Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses



• Ovulation inhibitory progesterone-only pills (i.e., desogestrel)



Because of the increased risk of venous thromboembolism in patients with multiple myeloma, combined oral contraceptive pills are not recommended (see section 4.5). If a patient is currently using combined oral contraception the patient should switch to one of the effective method listed above. The risk of venous thromboembolism continues for 4−6 weeks after discontinuing combined oral contraception.



Pregnancy testing:



Medically supervised pregnancy tests with a minimum sensitivity of 25 mIU/ml must be performed for women of childbearing potential as outlined below. This requirement includes women of childbearing potential who practice absolute and continuous abstinence.



Prior to starting treatment



A medically supervised pregnancy test should be performed during the consultation, when thalidomide is prescribed or in the 3 days prior to the visit to the prescriber once the patient had been using effective contraception for at least 4 weeks. The test should ensure the patient is not pregnant when she starts treatment with thalidomide.



Follow-up and end of treatment



A medically supervised pregnancy test should be repeated every 4 weeks, including 4 weeks after the end of treatment. These pregnancy tests should be performed on the day of the prescribing visit or in the 3 days prior to the visit to the prescriber.



Men:



As thalidomide is found in semen, male patients must use condoms during treatment and for 1 week after dose interruption and/or cessation of treatment if their partner is pregnant or is of childbearing potential not using effective contraception.



Prescribing and dispensing restrictions:



For women of childbearing potential, prescriptions of Thalidomide Celgene should be limited to 4 weeks of treatment and continuation of treatment requires a new prescription. Ideally, pregnancy testing, issuing a prescription and dispensing should occur on the same day. Dispensing of thalidomide should occur within a maximum of 7 days of the prescription.



For all other patients, prescriptions of Thalidomide Celgene should be limited to 12 weeks and continuation of treatment requires a new prescription.



Additional precautions:



Patients should be instructed never to give this medicinal product to another person and to return any unused capsules to their pharmacist at the end of treatment.



Patients should not donate blood or semen during therapy or for 1 week following discontinuation of thalidomide.



Educational materials:



In order to assist patients in avoiding foetal exposure to thalidomide and to provide additional important safety information, the Marketing Authorisation holder will provide educational material to healthcare professionals. The Thalidomide Celgene Pregnancy Prevention Programme reinforces the warnings about the teratogenicity of thalidomide, provides advice on contraception before therapy is started and provides guidance on the need for pregnancy testing. Full patient information about the teratogenic risk and the pregnancy prevention measures as specified in the Thalidomide Celgene Pregnancy Prevention Programme should be given by the physician to women of childbearing potential and, as appropriate, to male patients.



Cardiovascular disorders



Myocardial Infarction:



Myocardial infarction (MI) has been reported in patients receiving thalidomide, particularly in those with known risk factors. Patients with known risk factors for MI, including prior thrombosis, should be closely monitored and action should be taken to try to minimise all modifiable risk factors (e.g. smoking, hypertension, and hyperlipidaemia).



Venous and arterial thromboembolic events:



Patients treated with thalidomide have an increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event), see section 4.8. The risk appears to be greatest during the first 5 months of therapy. Thromboprophylaxis and dosing/anticoagulation therapy recommendations are provided in section 4.2.



Previous history of thromboembolic events or concomitant administration of erythropoietic agents or other agents such as hormone replacement therapy, may also increase thromboembolic risk in these patients. Therefore, these agents should be used with caution in multiple myeloma patients receiving thalidomide with prednisone and melphalan. Particularly, a haemoglobin concentration above 12g/dl should lead to discontinuation of erythropoietic agents. Action should be taken to try to minimize all modifiable risk factors (e.g. smoking, hypertension and hyperlipidaemia).



Patients and physicians are advised to be observant for the signs and symptoms of thromboembolism. Patients should be instructed to seek medical care if they develop symptoms such as shortness of breath, chest pain, arm or leg swelling.



Peripheral neuropathy:



Peripheral neuropathy is a very common, potentially severe, adverse reaction to treatment with thalidomide that may result in irreversible damage (see section 4.8). In a phase 3 study, the median time to first neuropathy event was 42.3 weeks.



If the patient experiences peripheral neuropathy, follow the dose and schedule modification instruction provided in section 4.2.



Careful monitoring of patients for symptoms of neuropathy is recommended. Symptoms include paraesthesia, dysaesthesia, discomfort, abnormal co-ordination or weakness.



It is recommended that clinical and neurological examinations are performed in patients prior to starting thalidomide therapy, and that routine monitoring is carried out regularly during treatment.



Medicinal products known to be associated with neuropathy should be used with caution in patients receiving thalidomide (see section 4.5).



Thalidomide may also potentially aggravate existing neuropathy and should therefore not be used in patients with clinical signs or symptoms of peripheral neuropathy unless the clinical benefits outweigh the risks.



Syncope and bradycardia:



Patients should be monitored for syncope and bradycardia and dose reduction or discontinuation may be required.



Skin reactions:



If at anytime the patient experiences a toxic skin reaction e.g. Stevens-Johnson Syndrome, the treatment should be discontinued permanently.



Somnolence:



Thalidomide frequently causes somnolence. Patients should be instructed to avoid situations where somnolence may be a problem and to seek medical advice before taking other medicinal products known to cause somnolence. Patients should be monitored and dose reduction may be required.



Patients should be advised as to the possible impairment of mental and/or physical abilities required for the performance of hazardous tasks (see section 4.7).



Tumour lysis syndrome:



The patients at risk of tumour lysis syndrome are those with high tumour burden prior to treatment. These patients should be monitored closely and appropriate precautions taken.



Patients with renal or hepatic impairment:



Studies conducted in healthy subjects and patients with multiple myeloma suggest that thalidomide is not influenced to any significant extent by renal or hepatic function (see section 5.2). However, this has not formally been studied in patients with impaired renal or hepatic function; therefore patients with severe renal or hepatic impairment should be carefully monitored for any adverse effects.



Lactose intolerance:



The capsules contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Thalidomide is a poor substrate for cytochrome P450 isoenzymes and therefore clinically important interactions with medicinal products metabolized by this enzyme system are unlikely. Non-enzymatic hydrolysis suggests that the potential for drug-drug interactions with thalidomide is low.



Increase of sedative effects of other medicinal products:



Thalidomide has sedative properties thus may enhance the sedation induced by anxiolytics, hypnotics, antipsychotics, H1 anti-histamines, opiate derivatives, barbiturates and alcohol. Caution should be used when thalidomide is given in combination with medicinal products that cause drowsiness.



Bradycardic effect:



Due to thalidomide's potential to induce bradycardia, caution should be exercised with medicinal products having the same pharmacodynamic effect such as active substances known to induce torsade de pointes, beta blockers or anticholinesterase agents.



Medicinal products known to cause peripheral neuropathy:



Medicinal products known to be associated with peripheral neuropathy (e.g. vincristine and bortezomib) should be used with caution in patients receiving thalidomide.



Hormonal contraceptives:



Thalidomide does not interact with hormonal contraceptives. In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 0.75 mg of ethinyl estradiol were studied. The results were similar with and without co-administration of thalidomide 200 mg/day to steady-state levels. However, combined hormonal contraceptives are not recommended due to the increased risk of venous thrombo-embolic disease.



Warfarin:



Multiple dose administration of 200 mg thalidomide q.d. for 4 days had no effect on the international normalized ratio (INR) in healthy volunteers. However, due to the increased risk of thrombosis in cancer patients, and a potentially accelerated metabolism of warfarin with corticosteroids, close monitoring of INR values is advised during thalidomide-prednisone combination treatment as well as during the first weeks after ending these treatments.



Digoxin:



Thalidomide does not interact with digoxin. In 18 healthy male volunteers, multiple dose administration of 200 mg thalidomide had no apparent effect on the single dose pharmacokinetics of digoxin. In addition, single dose administration of 0.5 mg digoxin had no apparent effect on thalidomide pharmacokinetics. It is not known whether the effect will be different in multiple myeloma patients.



4.6 Pregnancy And Lactation



Thalidomide Celgene is contraindicated during pregnancy and in women of childbearing potential unless all the conditions of the Thalidomide Celgene Pregnancy Prevention Programme are met (see section 4.3)



Thalidomide is a powerful human teratogen, inducing a high frequency (about 30%) of severe and live-threatening birth defects such as: ectromelia (amelia, phocomelia, hemimelia) of the upper and/or lower extremities, microtia with abnormality of the external acoustic meatus (blind or absent), middle and internal ear lesions (less frequent), ocular lesions (anophthalmia, microphthalmia), congenital heart disease, renal abnormalities. Other less frequent abnormalities have also been described.



Women of childbearing potential:



Women of childbearing potential must use one effective method of contraception for 4 weeks before therapy, during therapy, and during 4 weeks after thalidomide therapy (see section 4.4).



If pregnancy occurs in a woman treated with thalidomide, treatment must be stopped immediately and the patient should be referred to a physician specialised or experienced in teratology for evaluation and advice.



Male patients with female partners of childbearing potential:



As thalidomide is found in semen, male patients must use condoms during treatment and for 1 week after dose interruption and/or cessation of treatment when having sexual intercourse with a pregnant woman or with a woman with childbearing potential who is not using effective contraception.



If pregnancy occurs in a partner of male patient taking thalidomide, the female partner should be referred to a physician specialised or experienced in teratology for evaluation and advice.



Lactation:



It is unknown whether thalidomide is excreted in human breast milk. Animal studies have shown excretion of thalidomide in breast milk. Therefore breast-feeding should be discontinued during therapy with thalidomide.



4.7 Effects On Ability To Drive And Use Machines



No studies on the effects on the ability to drive and use machines have been performed.



However thalidomide may cause somnolence and blurred vision (see section 4.8). If affected, patients should be instructed not to drive cars, use machines or perform hazardous tasks while being treated with thalidomide.



4.8 Undesirable Effects



Most patients taking thalidomide can be expected to experience adverse reactions. The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are: neutropenia, leukopenia, constipation, somnolence, paraesthesia, peripheral neuropathy, anaemia, lymphopenia, thrombocytopenia, dizziness, dysaesthesia, tremor and peripheral oedema.



The clinically important adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone or dexamethasone include: deep vein thrombosis and pulmonary embolism, peripheral neuropathy, severe skin reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis, syncope, bradycardia, and dizziness (see sections 4.2, 4.4 and 4.5).



Table 2 contains only the adverse reactions for which a causal relationship with medicinal product treatment could reasonably be established. Frequencies given are based on the observations during a pivotal comparative clinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients. In addition to the adverse reactions noted in the pivotal study, adverse reactions related to thalidomide in combination with dexamethasone and also those based on post-marketing experience with the medicinal product are provided after Table 2.



Frequencies are defined as: very common (



Table 2: Frequency of adverse reactions with thalidomide in combination with melphalan and prednisone





































System Organ Class




Very Common




Common




Cardiac disorders




 



 




Cardiac failure



Bradycardia




Blood and lymphatic system disorders




Neutropenia



Leukopenia



Anaemia



Lymphopenia



Thrombocytopenia




 



 




Nervous system disorders




Peripheral neuropathy*



Tremor



Dizziness



Paraesthesia



Dysaesthesia



Somnolence




Abnormal coordination



 




Respiratory, thoracic and mediastinal disorders




 



 




Pulmonary embolism*



Interstitial lung disease



Bronchopneumopathy



Dyspnea




Gastrointestinal disorders




Constipation




Vomiting



Dry mouth




Skin and subcutaneous tissue disorders




 



 




Toxic skin eruption



Rash



Dry skin




Infections and infestations




 



 




Pneumonia




Vascular disorders




 



 




Deep vein thrombosis*




General disorders and administration site conditions




Peripheral oedema



 




Pyrexia



Asthenia



Malaise




Psychiatric disorders




 



 




Confusional state



Depression



* - See detailed section below



In addition to the adverse reactions outlined above thalidomide in combination with dexamethasone in other clinical studies led to the very common adverse reaction of fatigue; common adverse reactions of transient ischaemic event, syncope, vertigo, hypotension, mood altered, anxiety, blurred vision, nausea and dyspepsia; and uncommon adverse reactions of cerebrovascular accident, diverticular perforation, peritonitis, orthostatic hypotension and bronchitis.



Additional adverse reactions related to post-marketing experience with thalidomide and not seen in the pivotal study include: toxic epidermal necrolysis, intestinal obstruction, hypothyroidism, sexual dysfunction, tumour lysis syndrome, gastro-intestinal perforations, hypersensitivity, hearing impaired or deafness, renal failure, myocardial infarction and worsening of Parkinson's disease symptoms.



Blood and lymphatic system disorders:



Adverse reactions for haematological disorders are provided compared to the comparator arm, as the comparator has a significant effect on these disorders (Table 3)



Table 3: Comparison of haematological disorders for the melphalan, prednisone (MP) and melphalan, prednisone, thalidomide (MPT) combinations in study IFM 99-06 (see section 5.1)



























 


n (% of patients)


 

 


MP (n=193)




MPT (n=124)



 


Grades 3 and 4*


 


Neutropenia




57 (29.5)




53 (42.7)




Leukopenia




32 (16.6)




32 (25.8)




Anaemia




28 (14.5)




17 (13.7)




Lymphopenia




14 (7.3)




15 (12.1)




Thrombocytopenia




19 (9.8)




14 (11.3)



* WHO Criteria



Additional adverse reactions from post-marketing experience with thalidomide and not seen in the pivotal study include febrile neutropenia and pancytopenia.



Teratogenicity:



The risk of intra-uterine death or severe birth defects, primarily phocomelia, is extremely high. Thalidomide must not be used at any time during pregnancy (see sections 4.4 and 4.6).



Venous and arterial thromboembolic events:



An increased risk of venous thromboembolism (such as deep vein thrombosis and pulmonary embolism) and arterial thromboembolism (such as myocardial infarction and cerebrovascular event) has been reported in patients treated with thalidomide (see section 4.4).



Peripheral neuropathy:



Peripheral neuropathy is a very common, potentially severe, adverse reaction of treatment with thalidomide that may result in irreversible damage (see section 4.4). Peripheral neuropathy generally occurs following chronic use over a period of months. However, reports following relatively short-term use also exist. Incidence of neuropathy events leading to discontinuation, dose reduction or interruption increases with cumulative dose and duration of therapy. Symptoms may occur some time after thalidomide treatment has been stopped and may resolve slowly or not at all.



4.9 Overdose



Eighteen cases of overdose have been reported in the literature concerning doses up to 14.4 g. No fatalities have been reported and all overdose patients recovered without sequelae. There is no specific antidote for a thalidomide overdose. In the event of an overdose, the patient's vital signs should be monitored and appropriate supportive care given to maintain blood pressure and respiratory status.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: immunosuppressive agent, ATC code: L04AX 02.



Thalidomide has a chiral centre and is used clinically as a racemate of (+)-(R)- and (-)-(S)-thalidomide. The spectrum of activity of thalidomide is not fully characterised.



Thalidomide shows immunomodulatory anti-inflammatory and potential anti-neoplastic activities. Data from in vitro studies and clinical trials suggest that the immunomodulatory, anti-inflammatory and anti-neoplastic effects of thalidomide may be related to suppression of excessive tumour necrosis factor-alpha (TNF-α) production, down-modulation of selected cell surface adhesion molecules involved in leukocyte migration and anti-angiogenic activity. Thalidomide is also a non-barbiturate centrally active hypnotic sedative. It has no anti-bacterial effects.



Clinical efficacy:



Results from IFM 99-06, a Phase 3, randomised, open label, parallel group, multicentre study have demonstrated a survival advantage when thalidomide is used in combination with melphalan and prednisone for 12 cycles of 6 weeks in the treatment of newly diagnosed multiple myeloma patients. In this study the age range of patients was 65-75 years, with 41% (183/447) of patients 70 years old or older. The median dose of thalidomide was 217 mg and>40% of patients received 9 cycles. Melphalan and prednisone were dosed at 0.25 mg/kg/day and 2 mg/kg/day respectively on days 1 to 4 of each 6 weeks cycle.



Further to the per protocol analysis, an update was conducted for the IFM 99-06 study providing an additional 15 months follow-up data. The median overall survival (OS) was 51.6 ± 4.5 and 33.2 ± 3.2 months in the MPT and MP groups, respectively (97.5% CI 0.42 to 0.84). This 18 month difference was statistically significant with a hazard ratio of reduction of risk of death in the MPT arm of 0.59, 97.5% confidence interval of 0.42-0.84 and p-value of <0.001 (see Figure 1).



Figure 1: Overall survival according to treatment





5.2 Pharmacokinetic Properties



Absorption:



Absorption of thalidomide is slow after oral administration. The maximum plasma concentrations are reached 1-5 hours after administration. Co-administration of food delayed absorption but did not alter the overall extent of absorption.



Distribution:



The plasma protein binding of the (+)-(R) and (-)-(S) enantiomers was found to be 55% and 65% respectively. Thalidomide is present in the semen of male patients at levels similar to plasma concentrations. Therefore, because of the known severe teratogenic effects of the product, during treatment with thalidomide and for 1 week after stopping the treatment, male patients must use condoms if their partner is pregnant or is of childbearing potential not using effective contraception (see section 4.4).



Metabolism:



Thalidomide is metabolised almost exclusively by non-enzymatic hydrolysis. In plasma, unchanged thalidomide represents 80% of the circulatory components. Unchanged thalidomide was a minor component (<3% of the dose) in urine. In addition to thalidomide, hydrolytic products N-(o-carboxybenzoyl) glutarimide and phthaloyl isoglutamine formed via non-enzymatic processes are also present in plasma and in majority in urine. Oxidative metabolism does not contribute significantly to the overall metabolism of thalidomide. There is minimal cytochrome P450 catalysed hepatic metabolism of thalidomide. There are in vitro data indicating that prednisone may give rise to enzyme induction which could reduce the systemic exposure of concomitantly used medicinal products. The in vivo relevance of these findings is unknown.



Elimination:



The mean elimination half-life of thalidomide in plasma following single oral doses between 50 mg and 400 mg was 5.5 to 7.3 hours. Total systemic exposure (AUC) is proportional to dose at single-dose conditions. No time dependency of the pharmacokinetics has been observed. Following a single oral dose of 400mg of radio-labelled thalidomide, the total mean recovery was 93.6% of the administered dose by Day 8. The majority of the radioactive dose was excreted within 48 hour following dose administration. The major route of excretion was via the urine (>90%) while faecal excretion was minor.



There is a linear relationship between body weight and estimated thalidomide clearance; in MM patients with body weight from 47-133kg, thalidomide clearance ranged from approximately 6-12 L/h, representing an increase in thalidomide clearance of 0.621 L/h per 10kg body weight increase. However, the distribution of thalidomide is not influenced by age, gender, renal function and blood chemistry variables, to any significant level.



Hepatic and renal insufficiency:



The extent of thalidomide metabolism by the liver cytochrome P450 system is minimal and intact thalidomide is not excreted by the kidney. Measures of renal function (CLcr) and liver function (blood chemistry) indicate minimal effect of kidney and liver function on the pharmacokinetics of thalidomide. As such the metabolism of thalidomide is not expected to be affected by hepatic or renal dysfunction. Data from patients with end-stage renal disease suggest no impact of kidney function on thalidomide pharmacokinetics. However, considering that pharmacologically active metabolites are eliminated via urine, it is advised that patients with severe renal impairment should be carefully monitored for any adverse reactions.



5.3 Preclinical Safety Data



In the male dog, after one year of dosing, reversible bile plugs in canaliculi were observed at exposures greater than 1.9 fold the human exposure.



Decreased platelet counts were noted in the mouse and rat studies. The latter appears to be related to thalidomide and occurred at exposures greater than 2.4 fold the human exposure. This decrease did not result in clinical signs.



In a one-year dog study, enlarged and/or blue discoloration of mammary glands and prolonged estrus were observed in females at exposures equal to 1.8 or greater than 3.6-fold the human exposure, respectively. The relevance to humans is unknown.



The effect of thalidomide on thyroid function was assessed in both rats and dogs. No effects were observed in dogs; however in rats, there was an apparent dose-dependent decrease in total and free T4 that was more consistent in the female.



No mutagenic or genotoxic effect has been revealed when thalidomide was assayed in a standard battery of genotoxicity tests. No evidence of carcinogenicity was observed at exposures approximately 15, 13 and 39 times the estimated clinical AUC at the recommended starting dose in mice, male rats and female rats respectively.



Animal studies have demonstrated differences in species susceptibility to the teratogenic effects of thalidomide. In humans, thalidomide is a proven teratogen.



A study in rabbits demonstrated no effect on fertility indices in males or females although testicular degeneration was observed in males.



A peri and postnatal toxicity study performed in rabbits with thalidomide administered at doses up to 500 mg/kg/day resulted in abortions, increased stillbirths and decreased pup viability during lactation. Pups from mothers treated with thalidomide had increased abortions, reduced body weight gain, alterations in learning and memory, decreased fertility, and reduced pregnancy index.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Capsule contents:



Anhydrous lactose



Microcrystalline cellulose



Crospovidone (Type A)



Povidone (K90)



Stearic acid



Colloidal anhydrous silica



Capsule shell:



Gelatin



Titanium dioxide (E171)



Printing ink:



Shellac



Black iron oxide (E172)



Propylene glycol



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



This medicinal product does not require any special storage conditions.



6.5 Nature And Contents Of Container



PVC/PE/Aclar/aluminium blister containing 14 capsules



Pack sizes: 28 capsules (two blisters) in a wallet card.



6.6 Special Precautions For Disposal And Other Handling



All unused capsules should be returned to the pharmacist at the end of treatment.



7. Marketing Authorisation Holder



Celgene Europe Limited



1 Longwalk Road



Stockley Park



Uxbridge



UB11 1DB



United Kingdom



8. Marketing Authorisation Number(S)



EU/1/08/443/001



9. Date Of First Authorisation/Renewal Of The Authorisation



16/04/2008



10. Date Of Revision Of The Text



03/08/2011



Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.




Thursday, 5 April 2012

Ak-Dilate Ophthalmic


Generic Name: phenylephrine (Ophthalmic route)

fen-il-EF-rin

Commonly used brand name(s)

In the U.S.


  • AK-Dilate

  • Altafrin

  • Eye Cool

  • Mydfrin

  • Neofrin

  • Neo-Synephrine

  • Ocu-Phrin

  • Prefrin Liquifilm

Available Dosage Forms:


  • Solution

Therapeutic Class: Mydriatic-Cycloplegic


Pharmacologic Class: Sympathomimetic


Chemical Class: Alkylarylamine


Uses For AK-Dilate


Ophthalmic phenylephrine in strengths of 2.5 and 10% is used to dilate (enlarge) the pupil. It is used before eye examinations, before and after eye surgery, and to treat certain eye conditions. In the U.S., these preparations are available only with your doctor's prescription.


Before Using AK-Dilate


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Children may be especially sensitive to the effects of phenylephrine. This may increase the chance of side effects during treatment. In addition, the 10% strength is not recommended for use in infants. Also, the 2.5 and 10% strengths are not recommended for use in low birth weight infants.


Geriatric


Repeated use of 2.5 or 10% phenylephrine may increase the chance of problems during treatment with this medicine. In addition, heart and blood vessel problems have occurred more often in elderly patients than in younger adults.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Clorgyline

  • Iproniazid

  • Isocarboxazid

  • Nialamide

  • Phenelzine

  • Procarbazine

  • Rasagiline

  • Selegiline

  • Tranylcypromine

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Amitriptyline

  • Amoxapine

  • Clomipramine

  • Desipramine

  • Dothiepin

  • Doxepin

  • Furazolidone

  • Imipramine

  • Lofepramine

  • Midodrine

  • Nortriptyline

  • Opipramol

  • Pargyline

  • Protriptyline

  • Trimipramine

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Guanethidine

  • Propranolol

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Type 2 diabetes mellitus or

  • Heart or blood vessel disease or

  • High blood pressure—The 2.5 and 10% strengths of phenylephrine may make the condition worse

  • Idiopathic orthostatic hypotension (a certain kind of low blood pressure)—Use of this medicine may cause a large increase in blood pressure to occur

Proper Use of phenylephrine

This section provides information on the proper use of a number of products that contain phenylephrine. It may not be specific to AK-Dilate. Please read with care.


Do not use if the solution turns brown or becomes cloudy.


To use:


  • First, wash your hands. Tilt the head back and, pressing your finger gently on the skin just beneath the lower eyelid, pull the lower eyelid away from the eye to make a space. Drop the medicine into this space. Let go of the eyelid and gently close the eyes. Do not blink. Keep the eyes closed and apply pressure to the inner corner of the eye with your finger for 2 or 3 minutes to allow the medicine to be absorbed by the eye.

  • Immediately after using the eye drops, wash your hands to remove any medicine that may be on them.

  • To keep the medicine as germ-free as possible, do not touch the applicator tip to any surface (including the eye). Also, keep the container tightly closed.

For patients using the 2.5 or 10% eye drops:


  • It is very important that you use this medicine only as directed. Do not use more of it and do not use it more often than your doctor ordered. To do so may increase the chance of too much medicine being absorbed into the body and the chance of side effects. This is especially important when this medicine is used in children or in patients with heart disease or high blood pressure, since high doses of this medicine may cause an irregular heartbeat and an increase in blood pressure.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For ophthalmic solution (eye drops) dosage form:
    • For eye redness:
      • Adults and children—Use one drop of 0.12% solution every three or four hours as needed.


    • For eye exams:
      • Adults and children—Use one drop of 2.5% solution. Depending on the eye test to be done, it will take from fifteen minutes to one or two hours for the medicine to work before you can have the eye test.


    • For use before eye surgery:
      • Adults and teenagers—Use one drop of 2.5 or 10% solution thirty to sixty minutes before the start of eye surgery.

      • Children—Use one drop of 2.5% solution thirty to sixty minutes before the start of eye surgery.


    • For certain eye conditions:
      • Adults and teenagers—Depending on the eye condition being treated, your doctor may tell you to use one drop of 2.5 or 10% solution in the eye from once a day to three times a day.

      • Children—Depending on the eye condition being treated, your doctor may tell you to use one drop of 2.5% solution in the eye from once a day to three times a day.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


For non-prescription strength eye drops, follow the package directions.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Precautions While Using AK-Dilate


If eye pain or change in vision occurs or if redness or irritation of the eye continues, gets worse, or lasts for more than 72 hours, stop using the medicine and check with your doctor.


For patients using the 2.5 or 10% eye drops:


  • After you apply this medicine to your eyes, your pupils will become unusually large. This will cause your eyes to become more sensitive to light than they are normally. When you go out during the daylight hours, even on cloudy days, wear sunglasses that block ultraviolet (UV) light to protect your eyes from sunlight and other bright lights. Ordinary sunglasses may not protect your eyes. If you have any questions about the kind of sunglasses to wear, check with your doctor. Also, if this effect continues for longer than 12 hours after you have stopped using this medicine, check with your doctor.

AK-Dilate Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor as soon as possible if any of the following side effects occur:


Symptoms of too much medicine being absorbed into the body - Less common with 10% solution; rare with 2.5% or weaker solution
  • Dizziness

  • fast, irregular, or pounding heartbeat

  • increased sweating

  • increase in blood pressure

  • paleness

  • trembling

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common with 2.5 or 10% solution
  • Burning or stinging of eyes

  • headache or browache

  • sensitivity of eyes to light

  • watering of eyes

Less common
  • Eye irritation not present before use of this medicine

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: AK-Dilate Ophthalmic side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More AK-Dilate Ophthalmic resources


  • AK-Dilate Ophthalmic Side Effects (in more detail)
  • AK-Dilate Ophthalmic Use in Pregnancy & Breastfeeding
  • AK-Dilate Ophthalmic Drug Interactions
  • AK-Dilate Ophthalmic Support Group
  • 0 Reviews for AK-Dilate Ophthalmic - Add your own review/rating


Compare AK-Dilate Ophthalmic with other medications


  • Eye Dryness/Redness
  • Eye Redness/Itching
  • Pupillary Dilation

Tuesday, 3 April 2012

Jumexil




Jumexil may be available in the countries listed below.


Ingredient matches for Jumexil



Selegiline

Selegiline is reported as an ingredient of Jumexil in the following countries:


  • Brazil

Selegiline hydrochloride (a derivative of Selegiline) is reported as an ingredient of Jumexil in the following countries:


  • Brazil

International Drug Name Search

Monday, 2 April 2012

Albuterol extended-release tablets




Generic Name: Albuterol sulfate

Dosage Form: extended-release tablets

4 mg and 8 mg1


Rx only



1

(Each extended-release tablet contains 4.8 mg and 9.6 mg Albuterol sulfate equivalent to 4 mg and 8 mg Albuterol, respectively)


Albuterol Description


Albuterol sulfate extended-release tablets contain Albuterol sulfate, the racemic form of Albuterol and a relatively selective beta2-adrenergic bronchodilator, in an extended-release formulation. Albuterol sulfate has the chemical name (±) a1-[(tert-butyl-amino)methyl]-4-hydroxy-m-xylene-a, a´-diol sulfate (2:1) (salt), and the following structural formula:



Albuterol sulfate has a molecular weight of 576.7, and the molecular formula is (C13H21NO3)2•H2SO4. Albuterol sulfate, USP is a white crystalline powder, soluble in water and slightly soluble in ethanol.


The World Health Organization recommended name for Albuterol base is salbutamol.


Each tablet for oral administration contains 4 mg or 8 mg of Albuterol as 4.8 mg or 9.6 mg, respectively, of Albuterol sulfate, USP. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, triacetin and xanthan gum. The 8 mg tablets also contain the following coloring agents: FD&C Blue #2 aluminum lake and FD&C Yellow #6 aluminum lake.



Albuterol - Clinical Pharmacology


In vitro studies and in vivo pharmacologic studies have demonstrated that Albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicates that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established. (See WARNINGS.)


The pharmacologic effects of beta-adrenergic agonist drugs, including Albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors on intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3´, 5´-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.


Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.


Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase.



Preclinical


Intravenous studies in rats with Albuterol sulfate have demonstrated that Albuterol crosses the blood-brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the blood-brain barrier (pineal and pituitary glands), Albuterol concentrations were found to be 100 times those in the whole brain.


Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines were administered concurrently. The clinical significance of these findings is unknown.



Pharmacokinetics and Disposition


In a single-dose study comparing one 8 mg Albuterol sulfate extended-release tablet with two 4 mg immediate release Albuterol tablets, USP in 17 normal adult volunteers, the extent of availability of Albuterol sulfate extended-release tablets was shown to be about 80% of Albuterol tablets, USP with or without food. In addition, lower mean peak plasma concentration and longer time to reach the peak level were observed with Albuterol sulfate extended-release tablets as compared with Albuterol tablets, USP. The single-dose study results also showed that food decreases the rate of absorption of Albuterol from Albuterol sulfate extended-release tablets without altering the extent of bioavailability. In addition, the study indicated that food causes a more gradual increase in the fraction of the available dose absorbed from the extended-release formulation as compared with the fasting condition.


In another single-dose study in adults, 8 mg and 4 mg Albuterol sulfate extended-release tablets were shown to deliver dose proportional plasma concentrations in the fasting state. Definitive studies for the effect of food on 4 mg Albuterol sulfate extended-release tablets have not been conducted. However, since food lowers the rate of absorption of 8 mg Albuterol sulfate extended-release tablets, it is expected that food reduces the rate of absorption of 4 mg Albuterol sulfate extended-release tablets also.


Albuterol sulfate extended-release tablets have been formulated to provide duration of action of up to 12 hours. In an 8 day, multiple-dose, crossover study, 15 normal adult male volunteers were given 8 mg Albuterol sulfate extended-release tablets every 12 hours or 4 mg Albuterol tablets, USP every 6 hours. Each dose of Albuterol sulfate extended-release tablets and the corresponding doses of Albuterol tablets, USP were administered in the postprandial state. Steady-state plasma concentrations were reached within 2 days for both formulations. Fluctuations (Cmax−Cmin/Caverage) in plasma concentrations were similar for Albuterol sulfate extended-release tablets administered at 12 hour intervals and Albuterol tablets, USP administered every 6 hours. In addition, the relative bioavailability of Albuterol sulfate extended-release tablets was approximately 100% of the immediate release tablet at steady-state. A summary of these results is shown in the following table:



























Mean Values at Steady-State
CmaxCminTmaxT1/2AUC
(ng/mL)(ng/mL)(h)(h)(ng-h/mL)
Albuterol Sulfate

  Extended-Release

  Tablets
13.78.169.3134
Albuterol

  Tablets, USP
13.98.12.67.2132

The mean plasma Albuterol concentration versus time data at steady-state after the administration of Albuterol sulfate extended-release tablets 8 mg every 12 hours are displayed in the following graph:



Pharmacokinetic studies of 4 mg and 8 mg Albuterol sulfate extended-release tablets have not been conducted in pediatric patients. Bioavailability of 4 mg and 8 mg Albuterol sulfate extended-release tablets in pediatric patients relative to 2 mg and 4 mg immediate release Albuterol has been extrapolated from adult studies showing comparability at steady-state dosing and reduced bioavailability after single-dose administration.



Indications and Usage for Albuterol


Albuterol sulfate extended-release tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.



Contraindications


Albuterol sulfate extended-release tablets are contraindicated in patients with a history of hypersensitivity to Albuterol or any of its components.



Warnings


Immediate hypersensitivity reactions may occur after administration of Albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema.



Cardiovascular Effects


Albuterol sulfate extended-release tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of Albuterol sulfate extended-release tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol sulfate extended-release tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.



Deterioration of Asthma


Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol sulfate extended-release tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment; e.g., corticosteroids.



Use of Anti-Inflammatory Agents


The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents; e.g., corticosteroids.



Paradoxical Bronchospasm


Albuterol sulfate extended-release tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, Albuterol sulfate extended-release tablets should be discontinued immediately and alternative therapy instituted.


Rarely, erythema multiforme and Stevens-Johnson Syndrome have been associated with the administration of oral Albuterol in children.



Precautions



General


Albuterol, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.


In controlled clinical trials in adults, patients treated with Albuterol sulfate extended-release tablets had increases in selected serum chemistry values and decreases in selected hematologic values. Increases in SGPT were more frequent among patients treated with Albuterol sulfate extended-release tablets (12 of 247 patients, 4.9%) than among the theophylline (6 of 188 patients, 3.2%) and placebo (1 of 138 patients, 0.7%) groups. Increases in serum glucose concentration were also more frequent among patients treated with Albuterol sulfate extended-release tablets (23 of 234 patients, 9.8%) than among theophylline (11 of 173 patients, 6.45%) and placebo (3 of 129 patients, 2.3%) groups. Increases in SGOT were also more frequent among patients treated with Albuterol sulfate extended-release tablets (10 of 248 patients, 4%) and theophylline (5 of 193, 2.6%) than among patients treated with placebo.


Decreases in white blood cell counts were more frequent in patients treated with Albuterol sulfate extended-release tablets (10 of 247 patients, 4%) compared with patients receiving theophylline (2 of 185 patients, 1.1%) and patients receiving placebo (1 of 141 patients, 0.7%).


Decreases in hemoglobin and hematocrit were more frequent in patients receiving Albuterol sulfate extended-release tablets (16 of 228 patients, 7%, and 17 of 230 patients, 7.4%, respectively) than in patients receiving theophylline (5 of 171 patients, 2.9%, and 9 of 173 patients, 5.2%, respectively) and patients receiving placebo (5 of 129 patients, 3.9%, and 3 of 132 patients, 2.3%, respectively). The clinical significance of these results is unknown.


Large doses of intravenous Albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, Albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.



Information for Patients


Albuterol sulfate extended-release tablets must be swallowed whole with the aid of liquids. DO NOT CHEW OR CRUSH THESE TABLETS.


The action of Albuterol sulfate extended-release tablets should last up to 12 hours or longer. Albuterol sulfate extended-release tablets should not be used more frequently than recommended. Do not increase the dose or frequency of Albuterol sulfate extended-release tablets without consulting your physician. If you find that treatment with Albuterol sulfate extended-release tablets becomes less effective for symptomatic relief, your symptoms become worse, and/or you need to use the product more frequently than usual, you should seek medical attention immediately. While you are using Albuterol sulfate extended-release tablets, other inhaled drugs and asthma medications should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, tremor or nervousness. If you are pregnant or nursing, contact your physician about use of Albuterol sulfate extended-release tablets. Effective and safe use of Albuterol sulfate extended-release tablets includes an understanding of the way that it should be administered.



Drug Interactions


The concomitant use of Albuterol sulfate extended-release tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving Albuterol sulfate extended-release tablets. Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered.


Monoamine Oxidase Inhibitors or Tricyclic Antidepressants

Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of Albuterol on the vascular system may be potentiated.


Beta-Blockers

Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol sulfate extended-release tablets, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.


Diuretics

The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.


Digoxin

Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of Albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving Albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and Albuterol.



Carcinogenesis, Mutagenesis, Impairment of Fertility


In a 2 year study in Sprague-Dawley rats, Albuterol sulfate caused a significant dose related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg, (approximately 1/2, 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 2/5, 2, and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m2 basis).


In another study this effect was blocked by the coadministration of propranolol, a nonselective beta-adrenergic antagonist.


In an 18 month study in CD-1 mice, Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 65 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 50 times the maximum recommended daily oral dose for children on a mg/m2 basis).


In a 22 month study in the Golden hamster, Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of 50 mg/kg, (approximately 7 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis).


Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains S. typhimurium TA 1537, TA 1538, and TA98 or E. coli WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S. cerevisiae S9 nor any mitotic gene conversion in yeast strain S. cerevisiae JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. coli WP2, both with metabolic activation, were negative.


Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.


Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg, (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m2 basis).



Pregnancy


Teratogenic Effects. Pregnancy Category C

Albuterol sulfate has been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (SC) doses of 0.025, 0.25, and 2.5 mg/kg, (approximately 3/1000, 3/100, and 3/10 times the maximum recommended daily oral dose for adults on a mg/m2 basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest dose, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses of females treated with 2.5 mg/kg, of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m2 basis).


A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7/19 fetuses (37%) when Albuterol sulfate was administered orally at a 50 mg/kg dose, (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m2 basis).


There are no adequate and well controlled studies in pregnant women. Albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.


During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with Albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between Albuterol use and congenital anomalies has not been established.



Labor and Delivery


Because of the potential for beta-agonist interference with uterine contractility, use of Albuterol sulfate extended-release tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.


Tocolysis

Albuterol has not been approved for the management of pre-term labor. The benefit:risk ratio when Albuterol is administered for tocolysis has not been established. Serious adverse reactions, including pulmonary edema, have been reported during or following treatment of premature labor with beta2-agonists, including Albuterol.



Nursing Mothers


It is not known whether Albuterol is excreted in human milk. Because of the potential for tumorigenicity shown for Albuterol in animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use


The safety and effectiveness of Albuterol sulfate extended-release tablets have been established in pediatric patients 6 years of age or older. Use of Albuterol sulfate extended-release tablets in these age groups is supported by evidence from adequate and well controlled studies of Albuterol sulfate extended-release tablets in adults; the likelihood that the disease course, pathophysiology, and the drug's effect in pediatric and adult patients are substantially similar; the established safety and effectiveness of immediate release Albuterol tablets in pediatric patients 6 years of age and older; and clinical trials that support the safety of Albuterol sulfate extended-release tablets in pediatric patients over 6 years of age. The recommended dose of Albuterol sulfate extended-release tablets for the pediatric population is based upon the recommended pediatric dosing of immediate-release Albuterol tablets and pharmacokinetic studies in adults showing comparable bioavailability at steady-state dosing and reduced bioavailability after single-dose administration. Safety and effectiveness in pediatric patients below 6 years of age have not been established.



Adverse Reactions


The adverse reactions to Albuterol are similar in nature to reactions to other sympathomimetic agents.


The most frequent adverse reactions to Albuterol are nervousness, tremor, headache, tachycardia, and palpitations.


Less frequent adverse reactions are muscle cramps, insomnia, nausea, weakness, dizziness, drowsiness, flushing, restlessness, irritability, chest discomfort, and difficulty in micturition.


Rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema have been reported after the use of Albuterol.


In addition, Albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx.


In controlled clinical trials of adult patients conducted in the United States, the following incidence of adverse events was reported:






























































Albuterol Sulfate Extended-Release TabletsTheophyllineOther Beta-AgonistsPlacebo
Event(n = 330)(n = 197)(n = 20)(n = 178)
Tremor24.2%6.1%35%1.1%
Headache18.8%26.9%35%20.8%
Nervousness8.5%5.1%10%2.8%
Nausea/Vomiting4.2%19.8%5%3.9%
Tachycardia2.7%0.5%5%0%
Muscle Cramps2.7%0.5%5%0.6%
Palpitations2.4%0.5%0%1.1%
Insomnia2.4%6.1%0%1.7%
Dizziness1.5%2%0%5.1%
Somnolence0.3%1%0%0.6%

A trend was observed among patients treated with Albuterol sulfate extended-release tablets toward increasing frequency of muscle cramps with increasing patient age (12 to 20 years, 1.2%; 21 to 30 years, 2.6%; 31 to 40 years, 6.9%; 41 to 50 years, 6.9%), compared with no such events in the placebo group. Also observed was an increasing frequency of tremor with increasing patient age (12 to 20 years, 29.4%; 21 to 30 years, 29.9%; 31 to 40 years, 27.6%; 41 to 50 years, 37.9%), compared to 2.9% or less in the placebo group.


The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with Albuterol sulfate extended-release tablets.



Overdosage


The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS; e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. As with all sympathomimetic aerosol medications, cardiac arrest and even death may be associated with abuse of Albuterol sulfate extended-release tablets.


Treatment consists of discontinuation of Albuterol sulfate extended-release tablets together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Albuterol sulfate extended-release tablets.


The oral median lethal dose of Albuterol sulfate in mice is greater than 2000 mg/kg, (approximately 250 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 200 times the maximum recommended daily oral dose for children on a mg/m2 basis). In mature rats, the subcutaneous median lethal dose of Albuterol sulfate is approximately 450 mg/kg (approximately 110 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 90 times the maximum recommended daily oral dose for children on a mg/m2 basis). In small young rats, the subcutaneous median lethal dose is approximately 2000 mg/kg, (approximately 500 times the maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 400 times the maximum recommended daily oral dose for children on a mg/m2 basis).



Albuterol Dosage and Administration


The following dosages of Albuterol sulfate extended-release tablets are expressed in terms of Albuterol base:



Usual Dosage


Adults and Children Over 12 Years of Age

The usual recommended dosage for adults and pediatric patients over 12 years of age is 8 mg every 12 hours. In some patients, 4 mg every 12 hours may be sufficient.


Children 6 to 12 Years of Age

The usual recommended dosage for children 6 through 12 years of age is 4 mg every 12 hours.


Dosage Adjustment in Adults and Children Over 12 Years of Age

In unusual circumstances, such as adults of low body weight, it may be desirable to use a starting dosage of 4 mg every 12 hours and progress to 8 mg every 12 hours according to response.


If control of reversible airway obstruction is not achieved with the recommended doses in patients on otherwise optimized asthma therapy, the doses may be cautiously increased stepwise under the control of the supervising physician to a maximum dose of 32 mg per day in divided doses (i.e., every 12 hours).


Dosage Adjustment in Children 6 to 12 Years of Age

If control of reversible airway obstruction is not achieved with the recommended doses in patients on otherwise optimized asthma therapy, the doses may be cautiously increased stepwise under the control of the supervising physician to a maximum dose of 24 mg per day in divided doses (i.e., every 12 hours).


Switching From Oral Albuterol, USP Products

Patients currently maintained on Albuterol tablets, USP or Albuterol sulfate syrup can be switched to Albuterol sulfate extended-release tablets. For example, the administration of one 4 mg Albuterol sulfate extended-release tablet every 12 hours is comparable to one 2 mg Albuterol tablet, USP every 6 hours. Multiples of this regimen up to the maximum recommended daily dose also apply.



Albuterol sulfate extended-release tablets must be swallowed whole with the aid of liquids. DO NOT CHEW OR CRUSH THESE TABLETS.



How is Albuterol Supplied


Albuterol Sulfate Extended-release Tablets are available containing 4 mg and 8 mg of Albuterol.


The 4 mg tablets are white film-coated, round, unscored tablets debossed with M on one side of the tablet and 22 on the other side. They are available as follows:


NDC 0378-4122-01

bottles of 100 tablets


NDC 0378-4122-05

bottles of 500 tablets


The 8 mg tablets are blue film-coated, round, unscored tablets debossed with M on one side of the tablet and 24 on the other side. They are available as follows:


NDC 0378-4124-01

bottles of 100 tablets


NDC 0378-4124-05

bottles of 500 tablets


Store at 20° to 25°C (68° to 77°F). [See USP for Controlled Room Temperature.]


Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.



Mylan Pharmaceuticals Inc.

Morgantown, WV 26505


REVISED JULY 2006

ALBER:R1








Albuterol SULFATE 
Albuterol sulfate  tablet, film coated, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0378-4122
Route of AdministrationORALDEA Schedule    






































INGREDIENTS
Name (Active Moiety)TypeStrength
Albuterol Sulfate (Albuterol)Active4 MILLIGRAM  In 1 TABLET
colloidal silicon dioxideInactive 
hypromelloseInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
polydextroseInactive 
polyethylene glycolInactive 
sodium lauryl sulfateInactive 
titanium dioxideInactive 
triacetinInactive 
xanthan gumInactive 






















Product Characteristics
ColorWHITEScoreno score
ShapeROUNDSize6mm
FlavorImprint CodeM;22
Contains      
CoatingtrueSymbolfalse














Packaging
#NDCPackage DescriptionMultilevel Packaging
10378-4122-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-4122-05500 TABLET In 1 BOTTLE, PLASTICNone






Albuterol SULFATE 
Albuterol sulfate  tablet, film coated, extended release










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0378-4124
Route of AdministrationORALDEA Schedule    












































INGREDIENTS
Name (Active Moiety)TypeStrength
Albuterol Sulfate (Albuterol)Active8 MILLIGRAM  In 1 TABLET
colloidal silicon dioxideInactive 
hypromelloseInactive 
magnesium stearateInactive 
microcrystalline celluloseInactive 
polydextroseInactive 
polyethylene glycolInactive 
sodium lauryl sulfateInactive 
titanium dioxideInactive 
triacetinInactive 
xanthan gumInactive 
FD&C blue #2 aluminum lakeInactive 
FD&C yellow #6 aluminum lakeInactive 






















Product Characteristics
ColorBLUEScoreno score
ShapeROUNDSize6mm
FlavorImprint CodeM;24
Contains      
CoatingtrueSymbolfalse














Packaging
#NDCPackage DescriptionMultilevel Packaging
10378-4124-01100 TABLET In 1 BOTTLE, PLASTICNone
20378-4124-05500 TABLET In 1 BOTTLE, PLASTICNone

Revised: 05/2007Mylan Pharmaceuticals Inc.

More Albuterol resources


  • Albuterol Side Effects (in more detail)
  • Albuterol Dosage
  • Albuterol Use in Pregnancy & Breastfeeding
  • Drug Images
  • Albuterol Drug Interactions
  • Albuterol Support Group
  • 34 Reviews for Albuterol - Add your own review/rating


Compare Albuterol with other medications


  • Asthma, acute
  • Asthma, Maintenance
  • Bronchospasm Prophylaxis
  • COPD, Acute
  • COPD, Maintenance

Collagenase Santyl




Collagenase Santyl® Ointment

250 units/g

Rx only



DESCRIPTION


Collagenase Santyl® Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue.



CLINICAL PHARMACOLOGY


Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of detritus.1 Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. 2, 3, 4, 5, 6 Collagen in healthy tissue or in newly formed granulation tissue is not attacked. 2, 3, 4, 5, 6, 7, 8 There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier.



INDICATIONS AND USAGE


Collagenase Santyl® Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21



CONTRAINDICATIONS


Collagenase Santyl® Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.



PRECAUTIONS


The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase Santyl® Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin's solution and normal saline are compatible with Collagenase Santyl® Ointment.


Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia.


A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase Santyl® Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established.



ADVERSE REACTIONS


No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported.



OVERDOSAGE


No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine.



DOSAGE AND ADMINISTRATION


Collagenase Santyl® Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl® Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl® Ointment in the following manner:


  1. Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl® Ointment (See PRECAUTIONS), followed by a normal saline solution rinse.

  2. Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl® Ointment. Should the infection not respond, therapy with Collagenase Santyl® Ointment should be discontinued until remission of the infection.

  3. Collagenase SantyI® Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

  4. Use of Collagenase Santyl® Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.


HOW SUPPLIED


Collagenase Santyl® Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP.


Do not store above 25°C (77°F). Sterility guaranteed until tube is opened.


Collagenase Santyl® Ointment is available in 15 gram and 30 gram tubes.



REFERENCES


  1. Mandl, I., Adv Enzymol. 23:163,1961.

  2. Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75,1969.

  3. Mazurek, I., Med. Welt. 22:150, 1971.

  4. Zimmerman, WE., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185.

  5. Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975.

  6. Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975.

  7. Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974.

  8. Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973.

  9. German, F.M., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165.

  10. Haimovici, H. & Strauch, B., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177.

  11. Lee, L.K., & Ambrus, J.L., Geriatrics. 30:91, 1975.

  12. Locke, R.K., & Heifitz, N.M., J. Am. Pod. Assoc. 65:242, 1975.

  13. Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973.

  14. Barrett D., Jr., & Klibanski, A., Am. J. Nurs. 73:849, 1973.

  15. Bardfeld, L.A., J. Pod. Ed. 1:41, 1970.

  16. Blum, G., Schweiz. Rundschau Med Praxis. 62:820,1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36.

  17. Zaruba, F., Lettl, A., Brozkova, L., Skrdlantova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:499, 1974.

  18. Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978.

  19. Rehn, V.J., Med. Klin. 58:799, 1963.

  20. Krauss, H., Koslowski, L., & Zimmermann W.E., Langenbecks Arch. Klin. Chir. 303:23, 1963.

  21. Gruenagel, H.H., Med. Klin. 58:442, 1963.

Marketed by: HEALTHPOINT®


1-800-441-8227

Healthpoint, Ltd.

Fort Worth, Texas 76107


Manufactured for DFB Biotech, Inc.

Fort Worth, Texas 76107

US Gov't License #1745


Distributed by: DPT Laboratories, Ltd.

San Antonio, Texas 78215


Reorder Nos.

0064-5010-15 (15g tube)

0064-5010-30 (30g tube)


© 2009 Healthpoint, Ltd.


SANTYL is a registered trademark of Healthpoint, Ltd.


129128-0809



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL










Collagenase Santyl 
Collagenase Santyl  ointment










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0064-5010
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
COLLAGENASE (COLLAGENASE)COLLAGENASE250 U  in 1 g






Inactive Ingredients
Ingredient NameStrength
PETROLATUM 


















Product Characteristics
ColorWHITE (to off-white)Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
10064-5010-1515 g In 1 TUBENone
20064-5010-3030 g In 1 TUBENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
BLABLA10199510/18/2006


Labeler - HEALTHPOINT, LTD (965634504)
Revised: 01/2011HEALTHPOINT, LTD

More Collagenase Santyl resources


  • Collagenase Santyl Side Effects (in more detail)
  • Collagenase Santyl Use in Pregnancy & Breastfeeding
  • Collagenase Santyl Drug Interactions
  • Collagenase Santyl Support Group
  • 0 Reviews for Collagenase Santyl - Add your own review/rating


Compare Collagenase Santyl with other medications


  • Actinic Keratosis